Journal of Applied Organometallic Chemistry

2024, Volume 4, Issue 2

Review Article

Appraisal of the Impact of Applying Organometallic Compounds in Cancer Therapy

Abdul Razak Mohamed Sikkander [a,*] | Manoharan Meena [b] | Hazarathaiah Yadav [c] | Nitin Wahi [d] | V. Vidya Lakshmi [e]

[a]*Department of Chemistry, Velammal Engineering College, Chennai, India*
[b]*Department of Chemistry, R.M.K. Engineering College, Kavaraipettai, Chennai-India*
[c]*Department of Chemistry, Vel Tech Rangarajan Dr. Sakunthala R&D Institute of science&Technology, Avadi, Chennai, India*
[d]*Department of Bioinformatics, Pathfinder Research and Training Foundation, Gr. Noida-201308, U.P., India*
[e]*Department of Electronics &Communication Engineering, Velammal Engineering College, Chennai-600066, India*

Use your device to scan and read the article online

Citation A.R.M. Sikkander, M. Meena, H. Yadav, N. Wahi, V. Vidya Lakshmi **Appraisal of the Impact of Applying Organometallic Compounds in Cancer Therapy.** *J. Appl. Organomet. Chem.*, **2024**, *4*(2), 145-166.

https://doi.org/10.48309/JAOC.2024.433120.1154

Article info:
Submitted: 30 December 2023
Revised: 14 February 2024
Accepted: 11 March 2024

ID: JAOC-2312-1154
Checked for Plagiarism: Yes
Language Editor Checked: Yes

Keywords:
Satra platin, Organoplatinum (IV) complexes, Carboplatin, Combination therapies, Chemotherapeutic drug

ABSTRACT

Chemotherapy for cancer frequently uses organometallic compounds containing platinum, such as oxaliplatin, carboplatin, and cisplatin. They are effective against rapidly dividing cancer cells because they form DNA adducts that cause DNA damage and cell death. They work against rapidly dividing cancer cells because of their mechanism of action, which involves the formation of covalent DNA adducts that obstruct DNA replication and transcription. It is true that cisplatin, carboplatin, and oxaliplatin three platinum containing organometallic compounds, are frequently utilized in cancer chemotherapy. These substances belong to a group of medications called platinum-based chemotherapeutics, and they have been used to treat a number of cancer types. Covalent DNA adducts are formed by oxaliplatin, carboplatin, and cisplatin to produce their anticancer effects. These substances contain platinum atoms that attach to purine bases in DNA to create intrastrain and interstream cross-links. These cross-links damage DNA and cause cell death by interfering with transcription and DNA replication. Platinum-containing compounds are extremely cytotoxic, especially to rapidly dividing cancer cells, because they can cause damage to DNA. The discovery and application of organometallic compounds containing platinum mark a critical advancement in the cancer treatment, and these compounds are still essential parts of chemotherapy regimens. Ongoing research endeavors to ascertain novel compounds based on platinum or substitute metals that exhibit enhanced effectiveness and diminished adverse reactions. These substances are well-known for their capacity to cause DNA damage in quickly proliferating cells, which can result in cell cycle arrest and eventual cell death. Although these conventional platinum drugs have demonstrated efficacy in treating a range of cancers, side effects and resistance development are linked to them. The dynamic field of research aims to improve the overall effectiveness and tolerability of chemotherapy by searching for new anticancer agents. New compounds with improved properties will probably continue to surface as our knowledge of cancer biology and drug development methods grows, which will help cancer treatment approaches to evolve.

***Corresponding Authors: Abdul Razak Mohamed Sikkander** (*ams240868@gmail.com*)

Table of Contents

1. Introduction

Organometallic platinum compounds, which involve the combination of platinum with organic molecules, represent a newer and evolving area of research in cancer treatment [1-4]. These compounds aim to overcome some limitations of traditional platinum drugs, such as resistance and toxicity, by introducing structural modifications [5]. Research in the field of organometallic platinum compounds is ongoing, and scientists are exploring various strategies to optimize their effectiveness and minimize side effects [6]. These compounds offer a potential avenue for addressing challenges associated with traditional platinum drugs, and further clinical studies are needed to assess their safety and efficacy in a broader range of cancer types [7].

2. Method

Satraplatin is not an oral platinum drug; rather, it is an oral platinum-containing chemotherapy agent [8]. Satraplatin (also known as JM-216) is a platinum-based chemotherapeutic drug that was developed as an oral alternative to intravenous platinum drugs like cisplatin (Figure 1).

Satraplatin, also known as JM-216, is indeed a platinum-based chemotherapy agent designed to be taken orally [9]. It was developed as an alternative to traditional intravenous platinum drugs like cisplatin and carboplatin, which are commonly used in cancer treatment. Satraplatin is a part of the platinum-containing chemotherapy class of drugs, and its oral administration provides a more convenient option for patients compared to intravenous treatments [10]. Platinum-containing chemotherapy drugs work by forming DNA adducts and cross-links, interfering with the DNA structure in rapidly dividing cells, including cancer cells. This disruption ultimately leads to the inhibition of cell division and cell death [11].



Figure 1. Satraplatin (JM-216)

2.1. Efficacy of satraplatin

Satraplatin has been investigated for its efficacy in treating various types of cancers, including prostate cancer. Like other platinum-based drugs, it may be used in combination with other chemotherapy agents to enhance its therapeutic effects (Figure 2) [12].

The development and use of oral platinum-containing drugs represent an important advancement in cancer treatment, offering patients an alternative route of administration with potential benefits in terms of convenience and quality of life during the course of treatment [13]. It has been studied for its efficacy against various cancers, including prostate cancer. The unique feature of satraplatin is its oral administration, which offers potential advantages in terms of convenience and patient compliance [14].

2.2. Activation of satraplatin

Satraplatin is designed to undergo activation and form reactive platinum species within cancer cells, leading to DNA damage and subsequent cell death [15]. Satraplatin, like other platinum-based chemotherapy agents, is designed to undergo activation within cancer cells [16-28]. Once it enters the cancer cells, it undergoes a series of chemical reactions that result in the formation of reactive platinum species. These reactive species then bind to



Figure 2. Platinum-based drugs, it may be used in combination with other chemotherapy agents to enhance its therapeutic effects



Figure 3. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

cellular components, particularly DNA, forming adducts and cross-links (Figure 3) [29].

2.3. Formation of platinum-DNA adducts

The formation of platinum-DNA adducts interferes with the normal structure and function of DNA. This interference disrupts DNA replication and transcription processes in rapidly dividing cells, including cancer cells. As a consequence, the cancer cells experience DNA damage, and this damage can lead to cell cycle arrest and programmed cell death, a process known as apoptosis. By inducing DNA damage in cancer cells, satraplatin aims to selectively target and destroy cancerous cells while minimizing the impact on normal, healthy cells [30].

This mechanism of action is a common feature of platinum-based chemotherapy drugs and is part of their broader class known as alkylating agents. It's important to note that the specific details of satraplatin's activation and its interactions with cellular components may vary, and ongoing research continues to explore the nuances of its mechanisms to optimize its effectiveness in cancer treatment. One of its key attributes is an enhanced resistance profile compared to some traditional platinum drugs, potentially reducing the likelihood of developing resistance. One of the key attributes of satraplatin is its enhanced resistance profile compared to some traditional platinum drugs, such as cisplatin.

Resistance to chemotherapy drugs can be a significant challenge in cancer treatment, as cancer cells may develop mechanisms to evade the effects of the drugs over time. Satraplatin was developed with the aim of overcoming or reducing the likelihood of resistance that can occur with other platinum-based chemotherapeutic agents [31].

2.4. Enhanced resistance profile of satraplatin

The enhanced resistance profile of satraplatin may be attributed to its chemical structure, which can affect how cancer cells process and respond to the drug. This attribute is important because it may contribute to the drug's ability to remain effective over a more extended period, potentially providing a prolonged benefit in the treatment of certain cancers. Reducing the development of resistance is a crucial aspect of improving the long-term efficacy of chemotherapy in cancer patients. Researchers and pharmaceutical companies continue to explore and develop new agents with enhanced properties to address issues like resistance and improve the overall success of cancer treatment [32, 8].

2.5. Clinical trials of satraplatin's for safety and efficacy

Clinical trials have been conducted to evaluate satraplatin's safety and efficacy, particularly in prostate cancer, but its use has not been as widespread as intravenous platinum drugs like cisplatin or carboplatin. Satraplatin had indeed undergone clinical trials to assess its safety and efficacy, especially in the treatment of prostate cancer. Clinical trials are essential for evaluating the potential of a new drug, and they provide crucial data on its effectiveness, safety profile, and potential side effects. It is important to note that the availability and use of a drug can be influenced by various factors, including the results of clinical trials, regulatory approvals, market dynamics, and the emergence of new treatment options. While satraplatin showed promise in clinical trials, the decision to use a specific chemotherapy agent depends on a variety of factors, including the type and stage of cancer, patient characteristics, and overall treatment goals [33, 28].

As of my last update, satraplatin had not gained as much widespread use as intravenous platinum drugs like cisplatin or carboplatin. Its reasons could be multifaceted and may include factors such as the availability of alternative treatments, the evolving landscape of cancer therapeutics, and the need for further data on long-term safety and efficacy. It would be advisable to consult more recent sources, such as medical literature, regulatory agencies, or healthcare professionals, for the latest information on satraplatin or any other cancer treatments [34].

3. Zaragozic Acid A-Pt (IV) Complex

Zaragozic Acid A-Pt (IV) complex combining platinum with zaragozic acid for anticancer activity. Zaragozic Acid A is a natural product derived from a fungus, and it is known for its inhibitory activity against squalene synthase, an enzyme involved in cholesterol biosynthesis [35]. However, the use of Zaragozic Acid A in combination with platinum for anticancer activity is not a widely recognized or documented approach based on the information available up to my last update. The development of new anticancer compounds often involves a combination of different chemical entities to enhance therapeutic effects or address specific challenges, such as drug resistance. If there have been new studies or developments related to Zaragozic Acid A combined with platinum for anticancer activity, I recommend checking the latest scientific literature, research articles, or clinical trial databases for the most up-to-date information. Always consult with healthcare professionals or researchers who specialize in oncology for the latest and most accurate information on emerging cancer treatments and therapies [36]. However, it's possible that developments in research and new findings have occurred since then. If a Zaragozic Acid A-Pt (IV) complex has indeed been investigated and demonstrated promising anticancer activity, especially against ovarian cancer cells, it would be important to refer to the latest scientific literature, research articles, or official statements from research institutions for the most accurate and up-to-date information [37]. Scientific research is dynamic, and new findings may emerge over time. To obtain the latest and most accurate information regarding a Zaragozic Acid A-Pt (IV) complex and its potential anticancer activity, especially against ovarian cancer cells. The research is at an advanced stage, you may also find information on ongoing or completed clinical trials related to this complex through clinical trial databases [38].

4. Organoplatinum (IV) Complexes with Amino Acids

The concept of synthesizing organoplatinum (IV) complexes with amino acids to improve selectivity and reduce toxicity is indeed an area of research in the field of cancer treatment (Figure 4).
Researchers are exploring various strategies to enhance the efficacy and reduce the side effects of platinum-based chemotherapy, which is commonly used in cancer treatment (Figure 5).



Figure 4. Types of organ toxicity



Figure 5. Researchers are exploring various strategies to enhance the efficacy and reduce the side effects of platinum-based chemotherapy

Amino acids, being the building blocks of proteins and crucial for various cellular processes, are of interest in drug development [39-43]. By incorporating amino acids into platinum complexes, researchers aim to improve the drug selectivity for cancer cells, potentially reducing harm to healthy cells and minimizing toxic side effects. The design of these complexes can be tailored to exploit the specific characteristics of cancer cells, such as increased uptake of certain nutrients. In addition, modifying the structure of platinum complexes allows researchers to fine-tune their properties, including their reactivity and interaction with cellular components. While the development of organoplatinum (IV) complexes with amino acids is a promising avenue, it is important to note that research in this field is ongoing, and the specific compounds and strategies employed may vary. Checking the latest scientific literature and research articles will provide more detailed and up-to-date information on specific advancements in this area [44-53].

The idea behind such research is to design platinum compounds that not only maintain their anticancer activity, but also exhibit enhanced selectivity for cancer cells, thereby minimizing side effects on healthy tissues. The primary goal in designing platinum compounds with amino acids or other ligands is to strike a balance between maintaining the anticancer activity of the platinum complex and increasing its selectivity for cancer cells. This selectivity is crucial for minimizing side effects on healthy tissues, a common challenge associated with traditional chemotherapy. The rationale behind these efforts is to exploit the unique characteristics of cancer cells, such as differences in nutrient uptake or cell surface properties, to deliver the therapeutic agent preferentially to cancerous tissues (Figure 6).



Figure 6. The primary goal in designing platinum compounds with amino acids or other ligands is to strike a balance between maintaining the anticancer activity of the platinum complex and increasing its selectivity for cancer cells

This targeted approach aims to enhance the therapeutic index of the drug, meaning it is more effective against cancer cells while sparing normal, healthy cells from unnecessary damage. Continuously working to fine-tune the properties of platinum compounds, exploring different ligands, structures, and delivery mechanisms to optimize their efficacy and minimize toxicity. Such advancements contribute to the ongoing evolution of cancer treatment strategies, moving towards more personalized and targeted approaches that aim to improve patient outcomes and quality of life during and after treatment [54].

Amino acids can be used as ligands to create organoplatinum complexes, and these complexes can be tailored to interact with specific cellular targets, potentially increasing their effectiveness against cancer cells. Amino acids, which are the building blocks of proteins and play essential roles in cellular processes, can be utilized as ligands to create organoplatinum complexes. By incorporating amino acids into the structure of the platinum complex, researchers can tailor the properties of the compound to interact with specific cellular targets. The choice of amino acids as ligands is often strategic, as different amino



Figure 7. Continuously working to fine-tune the properties of platinum compounds, exploring different ligands, structures, and delivery mechanisms to optimize their efficacy and minimize toxicity

acids have distinct properties and affinities for certain cellular components. This allows researchers to design organoplatinum complexes with the potential to selectively target cancer cells. The idea is to take advantage of the unique characteristics of cancer cells, such as altered metabolism and increased demand for certain nutrients, to enhance the uptake and retention of the platinum complex within cancerous tissues [55,56].

Furthermore, the ability to customize the structure of these complexes provides a means to fine-tune their reactivity, stability, and overall behavior in the cellular environment. This level of customization allows researchers to optimize the complexes for the maximum effectiveness against cancer cells while minimizing the impact on healthy cells. The field of designing platinum complexes with amino acids as ligands is an exciting area of research within the broader context of developing targeted and personalized cancer therapies. It holds promise for improving the therapeutic index of platinum-based chemotherapy and reducing side effects associated with traditional cancer treatments [57-71].

In addition, modifying the structure of these complexes may influence their pharmacokinetics and toxicity profiles. Researchers have explored the synthesis of organoplatinum (IV) complexes with amino acids for cancer treatment. Modifying the structure of organoplatinum complexes, especially by incorporating amino acids as ligands, can indeed have a significant impact on their pharmacokinetics and toxicity profiles. The pharmacokinetics of a drug refers to how the body absorbs, distributes, metabolizes, and eliminates the substance. Altering the structure allows researchers to influence these processes in a way that can enhance the therapeutic properties of the drug. The goal is to design complexes that have favorable pharmacokinetic properties, allowing them to reach the target cancer cells in effective concentrations while minimizing exposure to healthy tissues. This optimization can improve the overall efficacy of the treatment [72].

Moreover, modifying the structure of the complexes also plays a crucial role in influencing their toxicity profiles. By customizing the chemical properties of the compound, researchers aim to reduce the side effects associated with traditional platinum-based chemotherapy. This is a critical consideration in improving the tolerability and quality of life for cancer patients undergoing treatment. The synthesis of organoplatinum (IV) complexes with amino acids is part of an ongoing effort to create more targeted and personalized cancer therapies, with the ultimate goal of enhancing treatment outcomes and



Figure 8. Platinum (IV) prodrugs are compounds where platinum is in a higher oxidation state compared to traditional platinum (II) drugs like cisplatin

minimizing adverse effects. As research in this field progresses, it contributes to the broader landscape of advancements in cancer treatment strategies. The goal is to enhance the therapeutic index of platinum-based drugs, making them more potent against cancer cells while reducing harm to normal cells. Enhancing the therapeutic index of platinum-based drugs is a central objective in the ongoing research and development of anticancer therapies. The therapeutic index is a measure of a drug's effectiveness against the target disease (in this case, cancer) relative to its potential toxicity to normal tissues. By improving the therapeutic index, researchers aim to make platinum-based drugs more potent against cancer cells while minimizing the adverse effects on healthy cells [73].

This approach is part of a broader trend in cancer research to develop more targeted and personalized treatments. By designing platinum complexes with specific properties, such as incorporating amino acids as ligands, researchers can exploit the unique characteristics of cancer cells to selectively deliver the therapeutic agent to tumors.

This targeted approach aims to maximize the impact on cancer cells while sparing normal tissues, thereby reducing the side effects associated with chemotherapy. Ultimately, the quest to enhance the therapeutic index is crucial for improving the overall effectiveness and tolerability of platinum-based drugs, contributing to advancements in cancer treatment and care [74].

5. Platinum (IV) Prodrugs with Organic Ligands

Platinum (IV) prodrugs are compounds where platinum is in a higher oxidation state compared to traditional platinum (II) drugs like cisplatin. These prodrugs are designed with organic ligands to improve their pharmacokinetics, enhance drug delivery, and reduce side effects (Figure 8) [75].

The rationale behind using platinum (IV) prodrugs is to create more stable compounds that can bypass some of the limitations associated with platinum (II) drugs. Platinum (IV) complexes are generally less reactive and more inert, allowing them to circulate in the bloodstream with reduced toxicity. Once inside cancer cells, these prodrugs can undergo reduction, typically in the lower oxygen concentrations found in tumor tissues, converting them into active platinum (II) species. The additional oxidation state provides increased stability to the complex, reducing nonspecific binding and side effects during circulation in the bloodstream. Organic ligands can be chosen to improve the drug's solubility and target specific biological pathways or cancer cell features, enhancing the drug's specificity for cancer cells [76, 31].



Figure 9. Cisplatin forms DNA adducts, leading to intrastrain crosslinks, which interfere with DNA replication and transcription, ultimately inducing cell death

By modifying the structure of the platinum complex, researchers aim to reduce the toxicity associated with traditional platinum drugs, such as cisplatin. The reduction of platinum (IV) to platinum (II) within cancer cells is often facilitated by the intracellular reducing environment, leading to the release of the active platinum species and subsequent DNA damage. This approach has led to the development of various platinum (IV) prodrugs with promising preclinical results. These compounds are being explored for their potential in treating different types of cancers for the most recent and specific information on platinum (IV) prodrugs with organic ligands and their applications in cancer treatment [77].

6. Results and Discussion

The study on platinum organometallic compounds in cancer treatment has been ongoing, with platinum-based drugs being widely used in chemotherapy. Cisplatin, carboplatin, and oxaliplatin are some of the well-known platinum-containing drugs that have been extensively studied. Keep in mind

that there may be new developments or findings after my last update [78].

6.1. Cisplatin

Mechanism of action: Cisplatin forms DNA adducts, leading to intrastrain crosslinks, which interfere with DNA replication and transcription, ultimately inducing cell death (Figure 9) [79].

Effectiveness: Cisplatin has shown efficacy against various solid tumors, including testicular, ovarian, bladder, and lung cancers [80].
Side Effects: Nephrotoxicity and ototoxicity are notable side effects. Researchers have been exploring ways to mitigate these side effects or develop derivatives with reduced toxicity [81].

6.2. Carboplatin

Carboplatin is a derivative of cisplatin with a different side effect profile. It is often used as an alternative to cisplatin, especially in cases where reduced nephrotoxicity is desirable [82].
Clinical Applications: Carboplatin is commonly used in the treatment of ovarian and lung cancers.

6.3. Oxaliplatin

Mechanism of action: Oxaliplatin induces DNA crosslinks, similar to cisplatin, but its spectrum of activity differs [83].
Applications: Oxaliplatin is primarily used in colorectal cancer treatment, often in combination with other chemotherapeutic agents.

6.4. Research advances and challenges

Resistance: Drug resistance remains a challenge, and researchers are investigating strategies to overcome or bypass resistance mechanisms [84].
Combination therapies: Platinum compounds are often used in combination with other drugs or treatment modalities to enhance their efficacy and reduce resistance [85].
Novel platinum compounds: Researchers continue to explore and design new platinum-based compounds with improved therapeutic profiles [86].

6.5. Future directions

Personalized Medicine: Tailoring treatment based on individual patient characteristics and tumor profiles [87].
Targeted Therapies: Developing platinum compounds that specifically target cancer cells, minimizing damage to healthy tissues.
Nanoparticle Delivery: Utilizing nanoparticles for targeted drug delivery to improve the selectivity and reduce side effects [88].
Nanoparticle delivery systems offer a promising approach for improving the delivery and therapeutic efficacy of platinum organometallic compounds, commonly used in cancer treatment. These delivery systems can enhance drug stability, improve bioavailability, and target specific tissues or cells) (Table 1).

Using these nanoparticle delivery systems can enhance the therapeutic effects of platinum organometallic compounds by improving drug delivery, reducing side effects, and increasing the overall efficacy in cancer treatment. The choice of the nanoparticle system depends on factors such as the nature of the drug, the desired release profile, and the specific characteristics of the target tissues or cells.

6.6. Challenges and considerations

Toxicity: Managing and minimizing the toxic side effects associated with platinum compounds [89-93].
Resistance mechanisms: Understanding and overcoming mechanisms of resistance to enhance treatment efficacy [94].
Clinical translation: Moving promising findings from the laboratory to clinical practice [95-99].

7. Future Perspective of Effect of Organometallic Platinum Compounds Applications on Cancer Therapy

The future perspective of organometallic platinum compounds in cancer therapy holds exciting possibilities as researchers continue to explore and develop innovative strategies to

Table 1. Types of nanoparticles, composition, and its effects

S. No.	Types of Nanoparticles	Composition	Effects
1	Liposomes	Liposomes are lipid-based nanoparticles	Liposomes can encapsulate platinum compounds, protecting them from degradation and reducing systemic toxicity. They can also enhance drug accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect.
2	Polymeric Nanoparticles	Nanoparticles made from biocompatible polymers	Polymeric nanoparticles can provide sustained release of platinum compounds, improving drug circulation time, and reducing the frequency of administration. They can be further designed for targeted drug delivery to specific cells or tissues.
3	Dendrimers	Hyperbranched macromolecules	Dendrimers can encapsulate platinum compounds and improve drug solubility. Their structure allows for precise control over drug release kinetics and surface modifications for targeting specific cells.
4	Nanocarriers with Targeting Ligands	Various nanoparticles functionalized with targeting ligands.	Nanocarriers can be decorated with ligands that recognize specific receptors overexpressed on cancer cells. This targeting improves the selectivity of platinum drug delivery to cancer cells, minimizing damage to healthy tissues.
5	Nanogels	Hydrogel-based nanoparticles	Nanogels can encapsulate platinum compounds and provide a responsive drug release system, triggered by factors such as pH or temperature. They offer a versatile platform for drug delivery.
6	Gold Nanoparticles	Nanoparticles made up of gold	Gold nanoparticles can serve as carriers for platinum drugs and also have imaging properties. They can enhance drug delivery and enable monitoring of therapeutic responses through imaging techniques.
7	Silica Nanoparticles	Nanoparticles made up of silica	Silica nanoparticles can encapsulate platinum compounds and provide a stable platform for drug delivery. Their porous structure allows for controlled release of the drug.
8	Carbon Nanotubes	Cylindrical carbon structures	Carbon nanotubes can be functionalized to carry platinum drugs. They offer unique properties for drug delivery, such as high surface area and the ability to penetrate cell membranes.

enhance their efficacy, reduce side effects, and overcome resistance.

7.1. Personalized medicine

Advances in understanding the genetic and molecular characteristics of tumors allow for personalized cancer treatment. Organometallic platinum compounds may be tailored to specific genetic profiles, enabling more targeted and effective therapy while minimizing side effects.

7.2. Combination therapies

Researchers are exploring the synergistic effects of combining organometallic platinum compounds with other anticancer agents, immunotherapies, or targeted therapies. Combinatorial approaches may enhance treatment outcomes and overcome resistance mechanisms.

7.3. Drug delivery systems

Continued development of advanced drug delivery systems, such as nanoparticle carriers,

liposomes, and targeted delivery approaches, may improve the pharmacokinetics and bioavailability of platinum compounds. These systems can enhance selective drug delivery to tumor sites, reducing off-target effects.

7.4. Overcoming resistance

Resistance to platinum-based chemotherapy remains a challenge. Future research may focus on understanding the molecular mechanisms of resistance and developing strategies to overcome it, potentially through the combination of multiple drugs or the use of novel platinum compounds with distinct mechanisms of action.

7.5. Immunomodulation

Researchers are investigating the immunomodulatory effects of platinum compounds. Modulating the immune response within the tumor microenvironment may enhance the body's natural defenses against cancer, and platinum compounds may play a role in this context.

Advancements in molecular targeting and precision medicine may lead to the development of platinum compounds that selectively target specific signaling pathways or molecular targets within cancer cells. This could enhance therapeutic efficacy while minimizing damage to healthy tissues.

7.6. Biomarker development

Identification of reliable biomarkers associated with response to platinum-based therapy can aid in patient selection and monitoring treatment effectiveness. Biomarker-driven approaches may guide clinicians in choosing the most effective treatment for individual patients.

7.7. Reducing toxicity

Future research may focus on designing platinum compounds with reduced toxicity to normal tissues. This could involve the development of prodrugs that are activated specifically within the tumor environment or the creation of compounds with improved safety profiles.

7.8. Innovative imaging techniques

Advances in imaging technologies can contribute to better monitoring of treatment responses and understanding drug distribution within the body. Real-time imaging may guide treatment decisions and improve overall patient outcomes.

7.9. Gene editing and nanotechnology

Emerging technologies, such as CRISPR-based gene editing and advanced nanotechnology, may offer novel ways to enhance the therapeutic effects of platinum compounds. Precision targeting at the genetic level and innovative delivery systems could revolutionize cancer treatment. As research progresses, the integration of these future perspectives into clinical practice has the potential to significantly improve the effectiveness of organometallic platinum compounds in cancer therapy, providing more tailored and less toxic treatment options for patients.

8. Conclusion

The application of organometallic platinum compounds in cancer therapy has had a profound impact on the treatment of various malignancies. Platinum-based drugs, such as cisplatin, carboplatin, and oxaliplatin, have demonstrated significant efficacy against a wide range of cancers. However, challenges such as drug resistance and side effects have prompted ongoing research to optimize their therapeutic potential. Organometallic platinum compounds have shown remarkable efficacy in the treatment of various cancers, including ovarian, testicular, lung, and colorectal cancers. Their ability to form DNA adducts and induce apoptosis contributes to their anti-tumor effects. Resistance to platinum-based chemotherapy remains a significant challenge. Future research aims to unravel the molecular mechanisms behind resistance and develop strategies to overcome or mitigate this obstacle, potentially through combination therapies or

the development of novel platinum compounds. Advances in drug delivery systems, such as nanoparticle carriers, provide opportunities to enhance the selective targeting of platinum compounds to tumor sites. This not only improves drug efficacy but also minimizes off-target toxicity, paving the way for more personalized and precise cancer treatment. The future of cancer therapy involving organometallic platinum compounds may lie in the exploration of combination therapies. Combining platinum drugs with other agents, including immunotherapies and targeted therapies, holds promise for synergistic effects and improved patient outcomes. In addition, personalized medicine approaches based on individual patient characteristics may further optimize treatment strategies. Ongoing research in drug design may lead to the development of new platinum compounds with enhanced therapeutic profiles, reduced toxicity, and novel mechanisms of action. This could address limitations associated with current platinum drugs and broaden the scope of their applications. Investigations into the immunomodulatory effects of platinum compounds and the identification of reliable biomarkers may provide valuable insights. Understanding the interplay between platinum drugs and the immune system could open new avenues for cancer treatment strategies, with biomarkers guiding treatment decisions. Efforts to reduce the toxicities associated with platinum compounds are crucial for improving patient safety and quality of life during cancer treatment. Developing prodrugs or alternative platinum compounds with improved safety profiles is a key consideration for future research. In instantaneous, while organometallic platinum compounds have been integral to cancer therapy, ongoing research endeavors are focused on addressing challenges and unlocking their full therapeutic potential. The future holds promise for more targeted, personalized, and effective cancer treatments, with innovations in drug design, delivery systems, and combination therapies contributing to advancements in the field. As these developments unfold, the impact of organometallic platinum compounds on cancer therapy is likely to continue evolving, offering new hope and possibilities for patients facing various malignancies.

Acknowledgements

I would like to acknowledge and give my warmest thanks to Dr. P. Mani Sankar, Former Vice Chancellor, Bharathidasan University, Trichy, and Tamil Nadu, India who made this work possible. I would also like to thank coauthors for letting my defense be an enjoyable moment. Finally, I would like to thank God, for letting me through all the difficulties.

Disclosure Statement

The authors declare that there are no conflicts of interest regarding the publication of this article.

Orcid

Abdul Razak Mohamed Sikkander
https://orcid.org/0000-0002-8458-7448

Manoharan Meena
https://orcid.org/0000-0001-6270-7333

Hazarathaiah Yadav
https://orcid.org/0000-0002-5124-879X

Nitin Wahi
https://orcid.org/0009-0005-2970-011X

V.Vidya Lakshmi
https://orcid.org/0009-0009-1328-0594

References

[1]. M. Yusuf, U. Chawla, N. Haque Ansari, M. Sharma, M. Asif, Perspective on metal-ligand coordination complexes and improvement of current drugs for neurodegenerative diseases (NDDs), *Advanced Journal of Chemistry, Section A*, **2023**, *6*, 31-49. [Crossref], [Google Scholar], [Publisher]

[2]. F. Hooriabad Saboor, A. Ataei, Decoration of metal nanoparticles and metal oxide nanoparticles on carbon nanotubes, *Advanced Journal of Chemistry, Section A*, **2024**, *7*, 122-145. [Crossref], [Publisher]

[3]. H. Pourfaraj, M. Zaefizadeh, A. Vojood, Synthesis and characterization of cisplatin magnetic nanocomposite, *Journal of Medicinal and Nanomaterials Chemistry*, **2023**, *5*, 92-105. [Crossref], [Google Scholar], [Publisher]

[4]. U. Ndagi, N. Mhlongo, M.E. Soliman, Metal complexes in cancer therapy–An update from drug design perspective, *Drug Design, Development and Therapy*, **2017**, 599-616. [Google Scholar], [Publisher]

[5]. C. Zhang, C. Xu, X. Gao, Q. Yao, Platinum-based drugs for cancer therapy and anti-tumor strategies, *Theranostics*, **2022**, *12*, 2115. [Crossref], [Google Scholar], [Publisher]

[6]. A.M. Florea, D. Büsselberg, Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects, *Cancers*, **2011**, *3*, 1351-1371. [Crossref], [Google Scholar], [Publisher]

[7]. L. Zhong, Y. Li, L. Xiong, W. Wang, M. Wu, T. Yuan, W. Yang, C. Tian, Z. Miao, T. Wang, Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives, *Signal Transduction and Targeted Therapy*, **2021**, *6*, 201. [Crossref], [Google Scholar], [Publisher]

[8]. A. Bhargava, U.N. Vaishampayan, Satraplatin: Leading the new generation of oral platinum agents, *Expert Opinion on Investigational Drugs*, **2009**, *18*, 1787-1797. [Crossref], [Google Scholar], [Publisher]

[9]. A.J. Armstrong, E.S. Garrett-Mayer, Y.-C.O. Yang, R. De Wit, I.F. Tannock, M. Eisenberger, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis, *Clinical Cancer Research*, **2007**, *13*, 6396-6403. [Crossref], [Google Scholar], [Publisher]

[10]. D. Tsvetkova, S. Ivanova, Application of approved cisplatin derivatives in combination therapy against different cancer diseases, *Molecules*, **2022**, *27*, 2466. [Crossref], [Google Scholar], [Publisher]

[11]. S. Dasari, P.B. Tchounwou, Cisplatin in cancer therapy: Molecular mechanisms of action, *European Journal of Pharmacology*, **2014**, *740*, 364-378. [Crossref], [Google Scholar], [Publisher]

[12]. A.-M. Florea, D. Büsselberg, Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects, *Cancers*, **2011**, *3*, 1351-1371. [Crossref], [Google Scholar], [Publisher]

[13]. V. O'neill, C. Twelves, Oral cancer treatment: Developments in chemotherapy and beyond, *British Journal of Cancer*, **2002**, *87*, 933-937. [Crossref], [Google Scholar], [Publisher]

[14]. A. Granja, M. Pinheiro, S. Reis, Epigallocatechin gallate nanodelivery systems for cancer therapy, *Nutrients*, **2016**, *8*, 307. [Crossref], [Google Scholar], [Publisher]

[15]. L. Galluzzi, I. Vitale, J. Michels, C. Brenner, G. Szabadkai, A. Harel-Bellan, M. Castedo, G. Kroemer, Systems biology of cisplatin resistance: Past, present and future, *Cell Death & Disease*, **2014**, *5*, e1257-e1257. [Crossref], [Google Scholar], [Publisher]

[16]. C. Stewart, C. Ralyea, S. Lockwood, Ovarian cancer: An integrated review, Seminars in Oncology Nursing, **2019**, 35, 151-156. [Crossref], [Google Scholar], [Publisher]

[17]. H. Song, W. Li, R. Qi, L. Yan, X. Jing, M. Zheng, H. Xiao, Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance, *Chemical Communications*, **2015**, *51*, 11493-11495. [Crossref], [Google Scholar], [Publisher]

[18]. S. Rottenberg, C. Disler, P. Perego, The rediscovery of platinum-based cancer therapy, *Nature Reviews Cancer*, **2021**, *21*, 37-50. [Crossref], [Google Scholar], [Publisher]

[19]. J. Holford, S. Sharp, B. Murrer, M. Abrams, L. Kelland, In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473, *British Journal of Cancer*, **1998**, *77*, 366-373. [Crossref], [Google Scholar], [Publisher]

[20]. F. Wu, Y. Du, J. Yang, B. Shao, Z. Mi, Y. Yao, Y. Cui, F. He, Y. Zhang, P. Yang, Peroxidase-like active nanomedicine with dual glutathione

depletion property to restore oxaliplatin chemosensitivity and promote programmed cell death, *ACS Nano*, **2022**, *16*, 3647-3663. [Crossref], [Google Scholar], [Publisher]

[21]. G. Doshi, G. Sonpavde, C.N. Sternberg, Clinical and pharmacokinetic evaluation of satraplatin, *Expert Opinion on Drug Metabolism & Toxicology*, **2012**, *8*, 103-111. [Crossref], [Google Scholar], [Publisher]

[22]. H. Choy, Satraplatin: An orally available platinum analog for the treatment of cancer, *Expert Review of Anticancer Therapy*, **2006**, *6*, 973-982. [Crossref], [Google Scholar], [Publisher]

[23]. E.L. van Dorp, A. Yassen, A. Dahan, Naloxone treatment in opioid addiction: The risks and benefits, *Expert Opinion on Drug Safety*, **2007**, *6*, 125-132. [Crossref], [Google Scholar], [Publisher]

[24]. L. Kelland, Broadening the clinical use of platinum drug–based chemotherapy with new analogues: Satraplatin and picoplatin, *Expert Opinion on Investigational Drugs*, **2007**, *16*, 1009-1021. [Crossref], [Google Scholar], [Publisher]

[25]. Y.R. Zheng, K. Suntharalingam, T.C. Johnstone, H. Yoo, W. Lin, J.G. Brooks, S.J. Lippard, Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery, *Journal of the American Chemical Society*, **2014**, *136*, 8790-8798. [Crossref], [Google Scholar], [Publisher]

[26]. M. Frezza, S. Hindo, D. Chen, A. Davenport, S. Schmitt, D. Tomco, Q. Ping Dou, Novel metals and metal complexes as platforms for cancer therapy, *Current Pharmaceutical Design*, **2010**, *16*, 1813-1825. [Crossref], [Google Scholar], [Publisher]

[27]. X. Yuan, W. Zhang, Y. He, J. Yuan, D. Song, H. Chen, W. Qin, X. Qian, H. Yu, Z. Guo, Proteomic analysis of cisplatin-and oxaliplatin-induced phosphorylation in proteins bound to Pt–DNA adducts, *Metallomics*, **2020**, *12*, 1834-1840. [Crossref], [Google Scholar], [Publisher]

[28]. H. Choy, C. Park, M. Yao, Current status and future prospects for satraplatin, an oral platinum analogue, *Clinical Cancer Research*, **2008**, *14*, 1633-1638. [Crossref], [Google Scholar], [Publisher]

[29]. J. Zhou, Y. Kang, L. Chen, H. Wang, J. Liu, S. Zeng, L. Yu, The drug-resistance mechanisms of five platinum-based antitumor agents, *Frontiers in Pharmacology*, **2020**, *11*, 343. [Crossref], [Google Scholar], [Publisher]

[30]. G.F. Weber, G.F. Weber, DNA damaging drugs, *Molecular Therapies of Cancer*, **2015**, 9-112. [Crossref], [Google Scholar], [Publisher]

[31]. R.L. Lucaciu, A.C. Hangan, B. Sevastre, L.S. Oprean, Metallo-drugs in cancer therapy: Past, present and future, *Molecules*, **2022**, *27*, 6485. [Crossref], [Google Scholar], [Publisher]

[32]. O. Eje, C. Ogbonna, C. Onoyima, F. Nduka, Huntington disease: Mechanism of pathogenesis and recent developments in its therapeutic strategies-A short review, *Journal of Chemical Reviews*, **2023**, *5*, 129-142. [Crossref], [Google Scholar], [Publisher]

[33]. L. Mehrdana, H. Safari, A. Maher, Crisis management in the face of covid-19 to control drug chemistry for cancer patients in different countries: A review study, *Journal of Chemical Reviews*, **2021**, *3*, 232-246. [Crossref], [Google Scholar], [Publisher]

[34]. R. Huang, P.K. Zhou, DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy, *Signal Transduction and Targeted Therapy*, **2021**, *6*, 254. [Crossref], [Google Scholar], [Publisher]

[35]. J. Bergstrom, M. Kurtz, D. Rew, A. Amend, J. Karkas, R. Bostedor, V. Bansal, C. Dufresne, F. VanMiddlesworth, O. Hensens, Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase, *Proceedings of the National Academy of Sciences*, **1993**, *90*, 80-84. [Crossref], [Google Scholar], [Publisher]

[36]. C.I. Liu, W.Y. Jeng, W.J. Chang, T.P. Ko, A.H.J. Wang, Binding modes of zaragozic acid A to

human squalene synthase and staphylococcal dehydrosqualene synthase, *Journal of Biological Chemistry*, **2012**, *287*, 18750-18757. [Crossref], [Google Scholar], [Publisher]

[37]. L. Ma, W. Cho, E.R. Nelson, Our evolving understanding of how 27-hydroxycholesterol influences cancer, *Biochemical pharmacology*, **2022**, *196*, 114621. [Crossref], [Google Scholar], [Publisher]

[38]. I. Giacomini, F. Gianfanti, M.A. Desbats, G. Orso, M. Berretta, T. Prayer-Galetti, E. Ragazzi, V. Cocetta, Cholesterol metabolic reprogramming in cancer and its pharmacological modulation as therapeutic strategy, *Frontiers in Oncology*, **2021**, *11*, 682911. [Crossref], [Google Scholar], [Publisher]

[39]. S. Mukhopadhyay, C.M. Barnés, A. Haskel, S.M. Short, K.R. Barnes, S.J. Lippard, Conjugated platinum (IV)− peptide complexes for targeting angiogenic tumor vasculature, *Bioconjugate Chemistry*, **2008**, *19*, 39-49. [Crossref], [Google Scholar], [Publisher]

[40]. M. Xie, D. Liu, Y. Yang, Anti-cancer peptides: Classification, mechanism of action, reconstruction and modification, *Open Biology*, **2020**, *10*, 200004. [Crossref], [Google Scholar], [Publisher]

[41]. M. Chehelgerdi, M. Chehelgerdi, O.Q.B. Allela, R.D.C. Pecho, N. Jayasankar, D.P. Rao, T. Thamaraikani, M. Vasanthan, P. Viktor, N. Lakshmaiya, Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation, *Molecular Cancer*, **2023**, *22*, 169. [Crossref], [Google Scholar], [Publisher]

[42]. G.J. Yoshida, Metabolic reprogramming: the emerging concept and associated therapeutic strategies, *Journal of experimental & clinical cancer research*, **2015**, *34*, 1-10. [Crossref], [Google Scholar], [Publisher]

[43]. E. Bortolamiol, F. Visentin, T. Scattolin, Recent advances in bioconjugated transition metal complexes for cancer therapy, *Applied Sciences*, **2023**, *13*, 5561. [Crossref], [Google Scholar], [Publisher]

[44]. S. Norn, H. Permin, E. Kruse, P.R. Kruse, Mercury--a major agent in the history of medicine and alchemy, *Dansk Medicinhistorisk Arbog*, **2008**, *36*, 21-40. [Google Scholar], [Publisher]

[45]. S. Waxman, K.C. Anderson, History of the development of arsenic derivatives in cancer therapy, *The Oncologist*, **2001**, *6*, 3-10. [Crossref], [Google Scholar], [Publisher]

[46]. S.P. Pricker, Medical uses of gold compounds: Past, present and future, *Gold Bulletin*, **1996**, *29*, 53-60. [Google Scholar], [Publisher]

[47]. U. Jungwirth, C.R. Kowol, B.K. Keppler, C.G. Hartinger, W. Berger, P. Heffeter, Anticancer activity of metal complexes: Involvement of redox processes, *Antioxidants & Redox Signaling*, **2011,** *15*. [Crossref], [Google Scholar], [Publisher]

[48]. H.F. Ji, X.J. Li, H.Y. Zhang, Natural products and drug discovery: can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?, *EMBO Reports*, **2009**, *10*, 194-200. [Crossref], [Google Scholar], [Publisher]

[49]. M. Frezza, S. Hindo, D. Chen, A. Davenport, S. Schmitt, D. Tomco, Q. Ping Dou, Novel metals and metal complexes as platforms for cancer therapy, *Current Pharmaceutical Design*, **2010**, *16*, 1813-1825. [Crossref], [Google Scholar], [Publisher]

[50]. P.C. Bruijnincx, P.J. Sadler, New trends for metal complexes with anticancer activity, *Current Opinion in Chemical Biology*, **2008**, *12*, 197-206. [Crossref], [Google Scholar], [Publisher]

[51]. V. Mourino, J.P. Cattalini, A.R. Boccaccini, Metallic ions as therapeutic agents in tissue engineering scaffolds: An overview of their biological applications and strategies for new developments, *Journal of the Royal Society*

Interface, **2012**, *9*, 401-419. [Crossref], [Google Scholar], [Publisher]

[52]. B.T. Benedetti, E.J. Peterson, P. Kabolizadeh, A. Martínez, R. Kipping, N.P. Farrell, Effects of noncovalent platinum drug–protein interactions on drug efficacy: Use of fluorescent conjugates as probes for drug metabolism, *Molecular Pharmaceutics*, **2011**, *8*, 940-948. [Crossref], [Google Scholar], [Publisher]

[53]. V. Milacic, D. Fregona, Q.P. Dou, Gold complexes as prospective metal-based anticancer drugs, *Histology and Histopathology*, **2008**. [Google Scholar], [Publisher]

[54]. L. Zhong, Y. Li, L. Xiong, W. Wang, M. Wu, T. Yuan, W. Yang, C. Tian, Z. Miao, T. Wang, Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives, *Signal Transduction and Targeted Therapy*, **2021**, *6*, 201. [Crossref], [Google Scholar], [Publisher]

[55]. E.L. Lieu, T. Nguyen, S. Rhyne, J. Kim, Amino acids in cancer, *Experimental & Molecular Medicine*, **2020**, *52*, 15-30. [Crossref], [Google Scholar], [Publisher]

[56]. M.J. Lukey, W.P. Katt, R.A. Cerione, Targeting amino acid metabolism for cancer therapy, *Drug Discovery Today*, **2017**, *22*, 796-804. [Crossref], [Google Scholar], [Publisher]

[57]. J.H. Kim, E. Reeder, S. Parkin, S.G. Awuah, Gold (I/III)-phosphine complexes as potent antiproliferative agents, *Scientific Reports*, **2019**, *9*, 12335. [Crossref], [Google Scholar], [Publisher]

[58]. J. Verma, C. Warsame, R.K. Seenivasagam, N.K. Katiyar, E. Aleem, S. Goel, Nanoparticle-mediated cancer cell therapy: Basic science to clinical applications, *Cancer and Metastasis Reviews*, **2023**, 1-27. [Crossref], [Google Scholar], [Publisher]

[59]. J.L. Cooper, P. Robinson, The argument for making large classes seem small, *New Directions for Teaching and Learning*, **2000**, *2000*, 5-16. [Crossref], [Google Scholar], [Publisher]

[60]. R.K. Jain, T. Stylianopoulos, Delivering nanomedicine to solid tumors, *Nature Reviews Clinical Oncology*, **2010**, *7*, 653-664. [Crossref], [Google Scholar], [Publisher]

[61]. C.M.J. Hu, L. Zhang, Therapeutic nanoparticles to combat cancer drug resistance, *Current Drug Metabolism*, **2009**, *10*, 836-841. [Crossref], [Google Scholar], [Publisher]

[62]. D. Peer, J.M. KarP, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy, *Nature Nanotechnology*, **2007**, *2*, 755. [Crossref], [Google Scholar], [Publisher]

[63]. C. Naud, C. Thébault, M. Carrière, Y. Hou, R. Morel, F. Berger, B. Diény, H. Joisten, Cancer treatment by magneto-mechanical effect of particles, a review, *Nanoscale Advances*, **2020**, *2*, 3632-3655. [Crossref], [Google Scholar], [Publisher]

[64]. C.J. Murphy, A.M. Vartanian, F.M. Geiger, R.J. Hamers, J. Pedersen, Q. Cui, C.L. Haynes, E.E. Carlson, R. Hernandez, R.D. Klaper, Biological responses to engineered nanomaterials: Needs for the next decade, *ACS Central Science*, **2015**, *1*, 117-123. [Crossref], [Google Scholar], [Publisher]

[65]. A.D. Morton, Waiting for gramsci: State formation, passive revolution and the international, *Millennium*, **2007**, *35*, 597-621. [Crossref], [Google Scholar], [Publisher]

[66]. A. Ghossain, M.A. Ghossain, History of mastectomy before and after Halsted, *Le Journal medical libanais. The Lebanese Medical Journal*, **2009**, *57*, 65-71. [Google Scholar], [Publisher]

[67]. R. Sankaranarayanan, K. Ramadas, S. Thara, R. Muwonge, G. Thomas, G. Anju, B. Mathew, Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India, *Oral Oncology*, **2013**, *49*, 314-321. [Crossref], [Google Scholar], [Publisher]

[68]. K. Wang, J.E. Tepper, Radiation therapy-associated toxicity: Etiology, management, and prevention, *CA: A Cancer Journal for Clinicians*,

2021, *71*, 437-454. [Crossref], [Google Scholar], [Publisher]

[69]. S.M. Bird, The 1959 meeting in Vienna on controlled clinical trials–A methodological landmark, *Journal of the Royal Society of Medicine*, **2015**, *108*, 372-375. [Crossref], [Google Scholar], [Publisher]

[70]. B. Cho, Intensity-modulated radiation therapy: a review with a physics perspective, *Radiation Oncology Journal*, **2018**, *36*, 1. [Crossref], [Google Scholar], [Publisher]

[71]. L.S. Goodman, M.M. Wintrobe, W. Dameshek, M.J. Goodman, A. Gilman, M.T. McLennan, Nitrogen mustard therapy: Use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders, *Journal of the American Medical Association*, **1946**, *132*, 126-132. [Crossref], [Google Scholar], [Publisher]

[72]. H.S. Oberoi, N.V. Nukolova, A.V. Kabanov, T.K. Bronich, Nanocarriers for delivery of platinum anticancer drugs, *Advanced Drug Delivery Reviews*, **2013**, *65*, 1667-1685. [Crossref], [Google Scholar], [Publisher]

[73]. T.C. Johnstone, G.Y. Park, S.J. Lippard, Understanding and improving platinum anticancer drugs–phenanthriplatin, *Anticancer Research*, **2014**, *34*, 471-476. [Google Scholar], [Publisher]

[74]. P. Krzyszczyk, A. Acevedo, E.J. Davidoff, L.M. Timmins, I. Marrero-Berrios, M. Patel, C. White, C. Lowe, J.J. Sherba, C. Hartmanshenn, The growing role of precision and personalized medicine for cancer treatment, *Technology*, **2018**, *6*, 79-100. [Crossref], [Google Scholar], [Publisher]

[75]. T.C. Johnstone, K. Suntharalingam, S.J. Lippard, The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs, *Chemical Reviews*, **2016**, *116*, 3436-3486. [Crossref], [Google Scholar], [Publisher]

[76]. G. Rezanejade Bardajee, S. Ghavami, S.S. Hosseini, A review on pH and temperature responsive gels in drug delivery, *Journal of Chemical Reviews*, **2020**, *2*, 80-89. [Crossref], [Google Scholar], [Publisher]

[77]. I.W. Achkar, N. Abdulrahman, H. Al-Sulaiti, J.M. Joseph, S. Uddin, F. Mraiche, Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway, *Journal of Translational Medicine*, **2018**, *16*, 1-12. [Crossref], [Google Scholar], [Publisher]

[78]. S. Dilruba, G.V. Kalayda, Platinum-based drugs: past, present and future, *Cancer Chemotherapy and Pharmacology*, **2016**, *77*, 1103-1124. [Crossref], [Google Scholar], [Publisher]

[79]. S. Zhu, N. Pabla, C. Tang, L. He, Z. Dong, DNA damage response in cisplatin-induced nephrotoxicity, *Archives of Toxicology*, **2015**, *89*, 2197-2205. [Crossref], [Google Scholar], [Publisher]

[80]. A. Brown, S. Kumar, P.B. Tchounwou, Cisplatin-based chemotherapy of human cancers, *Journal of Cancer Science & Therapy*, **2019**, *11*. [Google Scholar], [Publisher]

[81]. M.-P. Mingeot-Leclercq, P.M. Tulkens, Aminoglycosides: Nephrotoxicity, *Antimicrobial Agents and Chemotherapy*, **1999**, *43*, 1003-1012. [Crossref], [Google Scholar], [Publisher]

[82]. J. Małyszko, K. Kozłowska, L. Kozłowski, J. Małyszko, Nephrotoxicity of anticancer treatment, *Nephrology Dialysis Transplantation*, **2017**, *32*, 924-936. [Crossref], [Google Scholar], [Publisher]

[83]. S. Schoch, S. Gajewski, J. Rothfuß, A. Hartwig, B. Köberle, Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics, *International Journal of Molecular Sciences*, **2020**, *21*, 6928. [Crossref], [Google Scholar], [Publisher]

[84]. B. Mansoori, A. Mohammadi, S. Davudian, S. Shirjang, B. Baradaran, The different mechanisms of cancer drug resistance: a brief review, *Advanced Pharmaceutical Bulletin*,

2017, *7*, 339. [Crossref], [Google Scholar], [Publisher]

[85]. G. Fang, A. Zhang, L. Zhu, Q. Wang, F. Sun, B. Tang, Nanocarriers containing platinum compounds for combination chemotherapy, *Frontiers in Pharmacology*, **2022**, *13*, 1050928. [Crossref], [Google Scholar], [Publisher]

[86]. F. De Castro, E. Stefàno, E. De Luca, M. Benedetti, F.P. Fanizzi, Platinum-nucleos (t) ide compounds as possible antimetabolites for antitumor/antiviral therapy: Properties and perspectives, *Pharmaceutics*, **2023**, *15*, 941. [Crossref], [Google Scholar], [Publisher]

[87]. R. Singh, J.W. Lillard Jr, Nanoparticle-based targeted drug delivery, *Experimental and Molecular Pathology*, **2009**, *86*, 215-223. [Crossref], [Google Scholar], [Publisher]

[88]. S.R. McWhinney, R.M. Goldberg, H.L. McLeod, Platinum neurotoxicity pharmacogenetics, *Molecular Cancer Therapeutics*, **2009**, *8*, 10-16. [Crossref], [Google Scholar], [Publisher]

[89]. I. Predarska, M. Saoud, I. Morgan, P. Lönnecke, G.N. Kaluđerović, E. Hey-Hawkins, Triphenyltin (IV) carboxylates with exceptionally high cytotoxicity against different breast cancer cell lines, *Biomolecules*, **2023**, *13*, 595. [Crossref], [Google Scholar], [Publisher]

[90]. T.Y. Seiwert, J.K. Salama, E.E. Vokes, The chemoradiation paradigm in head and neck cancer, *Nature Clinical Practice Oncology*, **2007**, *4*, 156-171. [Crossref], [Google Scholar], [Publisher]

[91]. A. Ardizzoni, L. Boni, M. Tiseo, F.V. Fossella, J.H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non–small-cell lung cancer: an individual patient data meta-analysis, *Journal of the National Cancer Institute*, **2007**, *99*, 847-857. [Crossref], [Google Scholar], [Publisher]

[92]. L. Hess, M. Benham-Hutchins, T. Herzog, C.-H. Hsu, D. Malone, G. Skrepnek, M. Slack, D. Alberts, A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer, *International Journal of Gynecologic Cancer*, **2007**, *17*. [Crossref], [Google Scholar], [Publisher]

[93]. Z.N. Lei, Q. Tian, Q.X. Teng, J.N. Wurpel, L. Zeng, Y. Pan, Z.S. Chen, Understanding and targeting resistance mechanisms in cancer, *MedComm*, **2023**, *4*, e265. [Crossref], [Google Scholar], [Publisher]

[94]. E.L. Sauers, T.C.V. McLeod, R.C. Bay, Practice-based research networks, part I: clinical laboratories to generate and translate research findings into effective patient care, *Journal of Athletic Training*, **2012**, *47*, 549-556. [Crossref], [Google Scholar], [Publisher]

[95]. W.M. Tierney, C.C. Oppenheimer, B.L. Hudson, J. Benz, A. Finn, J.M. Hickner, D. Lanier, D.S. Gaylin, A national survey of primary care practice-based research networks, *The Annals of Family Medicine*, **2007**, *5*, 242-250. [Crossref], [Google Scholar], [Publisher]

[96]. D.S. Kadam, S.G. Patil, D. Mammen, S.D. Kadam, V.S. More, In silico molecular docking againstc-KIT tyrosine kinase and ADME studies of 4-thiazolidinone derivatives, *Journal of Appllied Organometallic Chemistry*, **2023**, *3*, 13-27. [Crossref], [Publisher]

[97]. M.B. Swami, G.R. Nagargoje, S.R. Mathapati, A.S. Bondge, A.H. Jadhav, S.P. Panchgalle, V.S. More, A magnetically recoverable and highly effectual Fe_3O_4 encapsulated MWCNTs nanocomposite for synthesis of 1,8-dioxo-octahydroxanthene derivatives, *Journal of Appllied Organometallic Chemistry*, **2023**, *3*, 184-198. [Crossref], [Google Scholar], [Publisher]

[98]. G.R. Nagargoje, A.S. Bondge, P.D. Kadam, K.I. Momin, S.B. Zangade, D.D. Kadam, S.P. Panchgalle, V.S. More. Quantification of Langlois Reagent by ^{19}F-NMR Spectroscopy, *Journal of Appllied Organometallic Chemistry*, **2023**, *3*, 213-223. [Crossref], [Publisher]

[99]. A. Lande, B. Kolapwar, P. Bhujbal, K. Karamunge, V. More, Preparation, characterization, and biological relevaance of

Co, Ni, and Zn complexes derived from 6, 6'-((1*E*, 1'*E*)-((1, 3-phenylenebis (methylene)) *bis* (azanylylidene)) *bis* (methanylyidene))-*bis* (2, 4-dibromophenol), *Rasayan Journal of Chemistry*, **2023**, *16*, 1063-1068. [Crossref], [Google Scholar], [Publisher]